probenecid has been researched along with Dermatomyositis in 5 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
Dermatomyositis: A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To report the efficacy of probenecid for calcinosis of juvenile dermatomyositis (JDM) and assess the changes in phosphorus metabolism during treatment." | 7.71 | Treatment of calcinosis in juvenile dermatomyositis with probenecid: the role of phosphorus metabolism in the development of calcifications. ( Amir, J; Harel, G; Harel, L; Korenreich, L; Straussberg, R, 2001) |
| "Childhood dermatomyositis is frequently complicated by deposition of calcium salts in the soft tissues." | 6.65 | Calcinosis in dermatomyositis treated with probenecid. ( Haavik, TK; Skuterud, E; Sydnes, OA, 1981) |
| "Probenecid was used to reduce calcinosis, resulting in remarkable improvement of calcinosis accompanied by normalization of serum phosphorus level and disability after 17 months of administration." | 5.33 | Efficacy of probenecid for a patient with juvenile dermatomyositis complicated with calcinosis. ( Eguchi, K; Ejima, E; Ida, H; Kawakami, A; Nakamura, H; Origuchi, T, 2006) |
| "To report the efficacy of probenecid for calcinosis of juvenile dermatomyositis (JDM) and assess the changes in phosphorus metabolism during treatment." | 3.71 | Treatment of calcinosis in juvenile dermatomyositis with probenecid: the role of phosphorus metabolism in the development of calcifications. ( Amir, J; Harel, G; Harel, L; Korenreich, L; Straussberg, R, 2001) |
| "Childhood dermatomyositis is frequently complicated by deposition of calcium salts in the soft tissues." | 2.65 | Calcinosis in dermatomyositis treated with probenecid. ( Haavik, TK; Skuterud, E; Sydnes, OA, 1981) |
| "Probenecid was used to reduce calcinosis, resulting in remarkable improvement of calcinosis accompanied by normalization of serum phosphorus level and disability after 17 months of administration." | 1.33 | Efficacy of probenecid for a patient with juvenile dermatomyositis complicated with calcinosis. ( Eguchi, K; Ejima, E; Ida, H; Kawakami, A; Nakamura, H; Origuchi, T, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakamura, H | 1 |
| Kawakami, A | 1 |
| Ida, H | 1 |
| Ejima, E | 1 |
| Origuchi, T | 1 |
| Eguchi, K | 1 |
| Iuliano, P | 1 |
| Lama, G | 1 |
| Skuterud, E | 1 |
| Sydnes, OA | 1 |
| Haavik, TK | 1 |
| Eddy, MC | 1 |
| Leelawattana, R | 1 |
| McAlister, WH | 1 |
| Whyte, MP | 1 |
| Harel, L | 1 |
| Harel, G | 1 |
| Korenreich, L | 1 |
| Straussberg, R | 1 |
| Amir, J | 1 |
1 review available for probenecid and Dermatomyositis
| Article | Year |
|---|---|
[Dermatomyositis and polymyositis].
Topics: Adrenal Cortex Hormones; Dermatomyositis; Edetic Acid; Etidronic Acid; Heart Diseases; Humans; Immun | 1982 |
1 trial available for probenecid and Dermatomyositis
| Article | Year |
|---|---|
Calcinosis in dermatomyositis treated with probenecid.
Topics: Calcinosis; Child; Clinical Trials as Topic; Dermatomyositis; Female; Humans; Probenecid | 1981 |
3 other studies available for probenecid and Dermatomyositis
| Article | Year |
|---|---|
Efficacy of probenecid for a patient with juvenile dermatomyositis complicated with calcinosis.
Topics: Anti-Inflammatory Agents; Calcinosis; Child; Cyclosporine; Dermatomyositis; Drug Therapy, Combinatio | 2006 |
Calcinosis universalis complicating juvenile dermatomyositis: resolution during probenecid therapy.
Topics: Adult; Bone Density; Calcinosis; Dermatomyositis; Glomerular Filtration Rate; Humans; L-Lactate Dehy | 1997 |
Treatment of calcinosis in juvenile dermatomyositis with probenecid: the role of phosphorus metabolism in the development of calcifications.
Topics: Calcinosis; Calcium; Child; Dermatomyositis; Female; Humans; Phosphorus; Probenecid; Radiography; Ur | 2001 |